Session Title: Research Spotlight: Musculoskeletal and Sports Medicine
Session Time: 11:00am-11:45am
Location: Research Hub - Live Theater
Disclosures: Prathap Jayaram, MD: Nothing to disclose
Objective: To assess the effects of low-dose aspirin (ASA) use on activation of growth factor release from freshly isolated human platelet rich plasma (PRP).
Design: Prospective open label fixed sequence study.
Setting: Clinic and controlled laboratory setting.
Participants: 12 healthy men between the ages of 25 and 31 years. Participants were not taking NSAIDs before the study and otherwise reported to be healthy. Normal leukogram and platelet count profiles were required for inclusion. Healthy men were included in an attempt to sample a more homogeneous PRP, given the known differences in composition of growth factors between male and female PRP. Young healthy men were also chosen to reduce potential variability from age and disease that could be present in sampling an elder population.
Interventions: Whole blood (WB), LR-PRP profile and growth factor profile (TGF-B1, VEGF, PDGF-AB) were quantified at the onset of the study, participants were placed on a 81-mg tablet of aspirin/day for 2 consecutive weeks. At day 14, WB, LR-PRP and growth factor profile analyses was performed on fresh samples (never frozen) to mimic clinical point-of-care applications.
Main Outcome Measures: Platelet Count, RBC, WBC, TGF-B1, PDGF-AB and VEGF Data are presented as mean ± SD. Differences among groups were evaluated by 2-way analysis of variance, followed by a Tukey multiple-comparisons test
Results: Daily ASA had a significant reduction in release of VEGF, TGFB-1 and PDFG from LR-PRP (P<.05) and no effect on the number of platelets and leukocytes measured in whole blood and LR-PRP. Consistent with its inhibitory role in AA signaling, ASA significantly inhibited AA-mediated release of all 3 growth factors measured in this study. Although ASA had no effect on thrombin-mediated release of VEGF and TGF-B1 from LR-PRP, ASA did partially block thrombin-mediated release of PDGF-AB.
Conclusions: Daily use of low-dose ASA reduces VEGF, PDGF-AB, and TGF-B1 expression in freshly isolated human LR-PRP.
Level of Evidence: Level II
To cite this abstract in AMA style:Jayaram P. Effects of Aspirin on Growth Factor Release from Freshly Isolated Leukocyte-rich Platelet-rich Plasma in Healthy Men: A Prospective Open Label Fixed-Sequence Study [abstract]. PM R. 2019; 11(S2)(suppl 2). https://pmrjabstracts.org/abstract/effects-of-aspirin-on-growth-factor-release-from-freshly-isolated-leukocyte-rich-platelet-rich-plasma-in-healthy-men-a-prospective-open-label-fixed-sequence-study/. Accessed October 23, 2021.
« Back to AAPM&R Annual Assembly 2019
PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/effects-of-aspirin-on-growth-factor-release-from-freshly-isolated-leukocyte-rich-platelet-rich-plasma-in-healthy-men-a-prospective-open-label-fixed-sequence-study/